Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results 09/01/25
Welcome to Cardiology Today â Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like Olezarsen and influenza vaccine. Key takeaway: Baxdrostat Lowers Resistant Hypertension: ALDO-RCT Results.
Article Links:
Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. (The New England journal of medicine)
Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. (The New England journal of medicine)
Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. (The New England journal of medicine)
Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. (The New England journal of medicine)
Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (The New England journal of medicine)
Full episode page: https://podcast.explainheart.com/podcast/baxdrostat-lowers-resistant-hypertension-aldo-rct-results-09-01-25/
đ Featured Articles
Article 1: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888739
Summary: This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.
Article 2: Apixaban for Extended Treatment of Provoked Venous Thromboembolism.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888734
Summary: This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.
Article 3: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888730
Summary: This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.
Article 4: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888720
Summary: This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.
Article 5: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Journal: The New England journal of medicine
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40888717
Summary: This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications.
đ Transcript
Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. This phase 3 trial investigated olezarsen, an N-acetylgalactosamine-conjugated antisense oligonucleotide targeting apolipoprotein C-III messenger Ribonucleic acid, in patients with moderate hypertriglyceridemia. Results showed olezarsen significantly reduced triglyceride levels compared to placebo in patients with elevated cardiovascular risk. This suggests a potential new therapeutic avenue for managing hypertriglyceridemia and reducing cardiovascular risk.
Article number two. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. This single-center, double-blind trial evaluated extended apixaban treatment for venous thromboembolism in patients with transient provoking factors and enduring risk factors. The study found that extended apixaban (2.5 milligrams twice daily) did not significantly reduce recurrent venous thromboembolism compared to placebo after at least three months of anticoagulation. This indicates that routine extended apixaban use may not be warranted in this specific patient population.
Article number three. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. This phase 3 multinational trial assessed baxdrostat, an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension. Baxdrostat significantly reduced seated systolic blood pressure compared to placebo, even in patients already on multiple antihypertensive medications. These findings support baxdrostat as a potential add-on therapy for resistant hypertension, targeting aldosterone dysregulation.
Article number four. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. This pragmatic, open-label, randomized, controlled trial in Denmark evaluated the effectiveness of high-dose influenza vaccine against hospitalization in older adults. The study demonstrated that the high-dose influenza vaccine did not significantly reduce the risk of hospitalization due to influenza compared to the standard dose vaccine. This challenges previous assumptions about the superior effectiveness of high-dose vaccines in preventing severe influenza outcomes in the elderly.
Article number five. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. This phase 3 international trial investigated mavacamten in adults with symptomatic nonobstructive Hypertrophic Cardiomyopathy. Mavacamten significantly improved functional capacity and patient-reported health status compared to placebo in this patient group. This suggests mavacamten could be a beneficial treatment option for symptomatic nonobstructive Hypertrophic Cardiomyopathy, expanding its therapeutic applications.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
Olezarsen, influenza vaccine, resistant hypertension, nonobstructive Hypertrophic Cardiomyopathy, systolic blood pressure, cardiovascular risk, hospitalization, provoking factors, aldosterone synthase inhibitor, high-dose vaccine, apixaban, functional capacity, anticoagulation, recurrent thrombosis, hypertension, cardiac myosin, antisense oligonucleotide, Hypertrophic Cardiomyopathy, venous thromboembolism, older adults, baxdrostat, vaccine effectiveness, mavacamten, apolipoprotein C-III, hypertriglyceridemia.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow